IP Library Granted Patent US 10,300,020
Granted Patent B2
US 10,300,020 · App. 14/541,819 · Granted May 28, 2019

Formulation and manufacturing process for calcium acetate capsules

Inventors: Julie Economou (Dublin, OH); Shehla Uraizee (Dublin, OH)
Assignee: WEST-WARD PHARMACEUTICALS INTERNATIONAL LIMITED
A61K9/4833A61K9/14A61K9/1635A61K9/1688A61K9/48A61K31/19
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,300,020
App. No.
14/541,819
Granted
May 28, 2019
Kind
B2
Abstract

The present invention relates to a pharmaceutical calcium acetate formulation and a process for making the same. In particular, the present invention relates to a calcium acetate capsule formulation comprising granules comprising calcium acetate along with other formulation adjuvants contained within a pharmaceutically acceptable capsule.

Claims (15)

1. A capsule containing a calcium acetate formulation comprising flowable granules, the flowable granules being comprised of calcium acetate and an adjuvant, and the flowable granules being granulating a dry blend comprising calcium acetate and an adjuvant under pressure in a roller compactor, wherein the flowable granules comprise a tap density, the tap density being such that 667 mg of the calcium acetate on an anhydrous basis of the flowable granules can be filed into a size 00 capsule.

2. The capsule of claim 1 , the granules being granulated under hydraulic pressure.

3. The capsule of claim 1 , the adjuvant being a lubricant, glidant, disintegrants or diluents.

4. The capsule of claim 3 , the adjuvant being polyethylene glycol.

5. The capsule of claim 3 , the adjuvant being magnesium stearate.

6. The capsule of claim 1 , the flowable granules not being compressed into a tablet or caplet before being filled into the capsule.

7. The capsule of claim 1 , the flowable granules being filled into the capsule using an encapsulation device.

8. The capsule of claim 1 , the capsule containing 667 mg of calcium acetate on an anhydrous basis.

9. The capsule of claim 1 , the capsule being size 00.

10. The capsule of claim 1 , the capsule having a dissolution in water such that at least 86% of the calcium acetate is dissoluted within 10 minutes.

11. The capsule of claim 1 , the capsule having a dissolution in water such that at least 96% of the calcium acetate is dissoluted within 15 minutes.

12. The capsule of claim 1 , the capsule having a dissolution in water such that at least 95% of the calcium acetate is dissoluted within 10 minutes.

13. The capsule of claim 1 , the capsule having a dissolution in water such that at least 100% of the calcium acetate is dissoluted within 15 minutes.

14. The capsule of claim 1 , the flowable granules having a median particle size of from about 450 microns to about 600 microns.

15. The capsule of claim 1 , the flowable granules being sized such that about 75% of the particles are retained on a 150 micron sieve.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2023
From: WEST-WARD PHARMACEUTICALS INTERNATIONAL LIMITED
To: HIKMA PHARMACEUTICALS USA INC.
Reel/Frame 065483/0819 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2018
From: ROXANE LABORATORIES INC.
To: WEST-WARD PHARMACEUTICALS INTERNATIONAL LIMITED
Reel/Frame 046190/0001 →
Continuity (4)
Continuation 14027650 · Sep 16, 2013
Division 11566938 · Dec 5, 2006
Provisional Application 60742502 · Dec 5, 2005
Related Publication 20150071996A1 · Mar 12, 2015